Celiac Disease
Pipeline by Development Stage
Drug Modality Breakdown
Gastroenterology is a $7.3B market characterized by mature, blockbuster-driven portfolios with near-term patent cliff risks.
Key Trends
- AbbVie dominance with 43% of top-10 product spending (LINZESS, CREON, RINVOQ)
- Guanylate cyclase activators and JAK inhibitors driving innovation in constipation and IBD
- Multiple patent expirations 2026–2030 creating biosimilar and generic erosion headwinds
Career Verdict
Gastroenterology offers stable, well-compensated roles but limited growth upside; best for risk-averse professionals seeking established markets over innovation-driven career trajectories.
AI-generated market analysis based on FDA, CMS, ClinicalTrials.gov, and hiring data
Market Leaders
| # | Product | Company | Revenue | Share | Stage | Trend | LOE |
|---|---|---|---|---|---|---|---|
| 1 | LINZESS (linaclotide) | AbbVie | $1.8B | 25% | Peak | Stable | 7.6yr |
| 2 | CREON (pancrelipase) | AbbVie | $1.5B | 21% | LOE Approaching | Declining | |
| 3 | XIFAXAN (rifaximin) | Bausch Health | $1.1B | 15% | LOE Approaching | Declining | |
| 4 | RINVOQ (upadacitinib) | AbbVie | $976M | 13% | Peak | Growing | 11.7yr |
| 5 | XELJANZ XR (tofacitinib) | Pfizer | $586M | 8% | Peak | Stable | 8.2yr |
Drug Class Breakdown
mature portfolio anchor
well-established class
facing biosimilar competition
growing IBD adoption
commoditized
Career Outlook
StableGastroenterology is a stable, mature market anchored by blockbusters with long patent runways (LINZESS to 2034, RINVOQ to 2038) but faces near-term erosion (XELJANZ 2026). Employment growth is modest and concentrated in device/diagnostic firms rather than pure-pharma. Best for professionals seeking predictable revenue streams over high-risk innovation bets.
Breaking In
Target roles at Roche, J&J, or diagnostic-adjacent firms to maximize hiring volume; pure pharma gastro entry points at AbbVie/Pfizer are limited and highly competitive.
For Experienced Professionals
Leverage gastro expertise in broader GI/immunology roles (Takeda, Novartis) or transition to medical devices/diagnostics where hiring is 3x higher than pharma.
In-Demand Skills
Best For
Hiring Landscape
Total hiring across the gastro ecosystem is 1,818 jobs, dominated by engineering (434) and commercial roles (269). Roche leads absolute hiring at 377 roles, followed by Johnson & Johnson (323) and GE HealthCare (293), reflecting broad medical device and diagnostic involvement alongside pharma. AbbVie's gastro-specific hiring (78 jobs) is modest relative to its portfolio dominance.
By Department
Manufacturing and commercial roles command premium salaries ($213K and $176K respectively), but total gastro-pharma hiring is concentrated in Roche and J&J, not pure-play GI companies.
Competitive Landscape
27 companies ranked by most advanced pipeline stage
Trial Timeline
Clinical trial activity over time
Showing 15 of 30 trials with date data
Clinical Trials (31)
Total enrollment: 7,331 patients across 31 trials
Randomized, Double Blind, Placebo-controlled Phase 2 Study in Adults With Celiac Disease
Evaluating the Efficacy and Tolerability of ZED1227 in Subjects With Non-responsive Celiac Disease
A Study to Assess the Safety of TPM502 in Adults With Celiac Disease
Study of Latiglutenase in T1D/CD Patients
PRV-015 in Gluten-free Diet Non-responsive Celiac Disease
Prospective, Randomized, Double-Blind, Placebo-Controlled, Crossover Study in Symptomatic CD Patients
Study of the Safety, Pharmacodynamics, Efficacy, and PK of TIMP-GLIA in Subjects With Celiac Disease
A Double-blind Placebo-controlled Study to Evaluate Larazotide Acetate for the Treatment of Celiac Disease
Inoculating Celiac Disease Patients With the Human Hookworm Necator Americanus: Evaluating Immunity and Gluten-sensitivity
AMG 714 20060349 Multiple Dose Study in Moderate to Severe Psoriasis Subjects
A Study of Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of KAN-101 in Celiac Disease (ACeD-it)
Safety and Systemic Exposure Study of BL-7010 in Well-Controlled Celiac Patients.
A First-in-Patient Study to Evaluate the Safety and Tolerability of HB-2121 as a Diagnostic for Celiac Disease
A First-in-human Study to Evaluate the Safety and Tolerability of HB-2121 as a Diagnostic for Celiac Disease
VTP-1000 in Adults With Celiac Disease
Study of the Safety, Tolerability, Pharmacokinetics and Biomarker of DONQ52 in Celiac Disease Patients
PTG-100 for Patients With Celiac Disease
Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of GSK3915393 in Healthy Participants and to Evaluate the Interaction Between GSK3915393 and Grapefruit Juice and Itraconazole
Gluten Challenge Study in Celiac Disease Participants (MK-0000-402)
Assessment of KAN-101 in Celiac Disease (ACeD)
Study of the Safety, Tolerability and Pharmacokinetics of TIMP-GLIA in Subjects With Celiac Disease
Hookworm Therapy for Coeliac Disease
Simvastatin Metabolism as a Test for CD Activity (IRB 15-007568]
AMG 714 Expanded Access Program
Immune Responses to Gluten
Behavioral Intervention for Celiac Disease
T Cell Receptor (TCR) Sequencing and Transcriptional Profiling in Adult Celiac Disease Patients Undergoing Gluten Challenge
SCREENING OF CELIAC DISEASE IN SCHOLAR CHILDREN IN ITALY
Celiac Disease and Unexplained Iron Deficiency in a Primary Care Setting
Performance Evaluation of Capsule Endoscopy in the Diagnosis of Gluten Sensitive Enteropathy (MA-23)
Related Jobs in Gastroenterology
International Omnichannel Marketing Specialist
R-D Engineer II
Architecture & Technology Engineer – Medical & Diagnostics
Sr. Staff Engineer - Web Developer
IT Business Analyst - EDI
Senior Change Management Manager
Phase Legend
Key Insights
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.